DOI: 10.1055/s-00000020

Geburtshilfe und Frauenheilkunde

References

Tewari KS, Sill MW, Penson RT. et al.
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).

Lancet 2017;
390: 1654-1663
DOI: 10.1016/S0140-6736(17)31607-0.

Download Bibliographical Data

Access:
Access: